Skip to main content
News Geyer 11.2021
left: Prof. Matthias Geyer; right: Ines Kaltheuner
© David Fußhöller / UKB

News categories: Publication

Abemaciclib inhibits kinases involved in transcriptional regulation

Protein structures of Homeodomain-interacting protein kinase (HIPK) and dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) reveals abemaciclib as potent inhibitor

Abemaciclib is a widely used drug in the therapy of hormone-receptor positive (HR-positive) and human epidermal growth factor receptor negative (HER2-negative) advanced breast cancer. The drug functions as a direct inhibitor of cyclin-dependent kinases 4 and 6 (Cdk4/Cdk6). Both kinases are responsible for the deactivation of retinoblastoma protein (Rb) by phosphorylation. Until its deactivation, Rb prevents cell cycle progression. The defective functionality of Rb in several major cancers leads to extensive cell growth and tumor progression. Direct targeting and inactivation of Cdk4/Cdk6 by abemaciclib prevents Rb deactivation and reduces therefore oncogenic cell proliferation.

Prof. Matthias Geyer, Director of the Institute of Structural Biology and member of the Cluster of Excellence ImmunoSensation2 at the University Clinics Bonn, and his team now show that abemaciclib also acts as potent inhibitor of further kinases involved in transcriptional regulation. In collaboration with the team of Prof. Nathanael Gray from the Dana-Farber Cancer Institute at Harvard Medical School, Boston, the scientists found Homeodomain-interacting protein kinases (HIPKs) and dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) to be inhibitable by abemaciclib. Both proteins are auto-activated and supposed to directly act in transcriptional regulation, as recombinant HIPKs and DYRK1A phosphorylate the negative elongation factor SPT5, the transcription factor c-Myc, and the C-terminal domain of RNA polymerase II.

By providing crystal structures of HIPK3 and DYRK1A bound to abemaciclib respectively, Prof. Geyer and his team show that abemaciclib-binding occurs to the hinge region of the kinases. Hence, the interaction occurs in a similar mode as previously observed for Cdk4 and Cdk6. “HIPKs and DYRK1A are closely related kinases and both are targeted by abemaciclib with similar efficacy as Cdk4/6.” Prof. Geyer states.

Like Cdk4 and Cdk6, HIPKs are involved in the pathologies of various cancers, but also other conditions like diabetes type II, chronic fibrosis, Alzheimer´s and Huntington´s disease. The crystal structures of HIPK3 and DYRK1A in complex with abemaciclib provided now, add to the understanding of the mode of action of the clinically used inhibitor. “Also, this work opens up new opportunities for the structure-guided design of small-molecule compounds targeting HIPKs” adds Ines Kaltheuner, PhD Student at the Institute of Structural Biology.


Participating institutions and funding

Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02215, USA. This work was supported by a grant of the DFG (GE 976/9-2) and by a grant from the Deutsche Krebshilfe (70114008).


Publication

Ines H. Kaltheuner et al. (2021). Abemaciclib is a potent inhibitor of DYRK1A and HIP kinases involved in transcriptional regulation. Nature Communications 12:6607. https://www.nature.com/articles/s41467-021-26935-z


Contact

Prof. Matthias Geyer

Institute of Structural Biology

Biomedical Center

University of Bonn

Venusberg-Campus 1

53127 Bonn, Germany

phone: +49 228 287-51400

fax: +49 228 287-51221

e-mail: matthias.geyer@uni-bonn.de

Related news

AG Kürthen Multiple Sclerosis Bonn

News categories: Publication

Potential target for MS therapy discovered

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system caused by the immune system. B cells, which are a type of white blood cell, play a role in the development of MS and are thus a target for therapies. Researchers at the University Hospital Bonn (UKB), the University of Bonn and the FAU Erlangen-Nuremberg identified the membrane protein MLC1 as a potential target antigen in MS. The results of the work have now been published in the renowned journal “Neurology Neuroimmunology & Neuroinflammation”.
View entry
NLRP3 Alzheimers McManus

News categories: Publication

Reducing Neuroinflammation Could Help Fight Alzheimer’s

Alzheimer’s disease is the most common cause of dementia. A promising approach for its treatment is the prevention of inflammatory processes in the brain. An international team of scientists around Dr. Róisín McManus, Prof. Eicke Latz and Prof. Michael Heneka now provide new evidence supporting this approach and potentially contributing to the development of more effective therapies. The results have now been published in the journal “Immunity”.
View entry
Bipolar disorder News Noethen

News categories: Publication

Large study on the genetics of bipolar disorder

Genetic factors play a major role in the development of bipolar disorder. In an effort to better understand the underlying biology, researchers are constantly studying the genetic makeup of people with bipolar disorder. The Psychiatric Genomics Consortium's Genome-Wide Association Study (GWAS) is the largest of its kind. The study analyzes data from ver 150,000 people of European, East Asian, African-American and Latin American descent. The latest results have now been published in the renowned scientific journal “Nature”.
View entry

Back to the news overview